

Patient Signature (I agree to terms on the next page):

Medical Professional Signature (I agree to terms on the next page):

Cancer Test Requisition Form (Abbreviated)

COMPLETE ENTIRE FORM AND SUBMIT PEDIGREE/CLINIC NOTES TO AVOID DELAYS

To submit an order via email, please send the completed test requisition form to info@ambrygen.com

Date:

Date:

1. SPECIMEN INFORMATION (Please see ambrygen.com/specimen-requirements for details)														, 0
Collection Date	ill Ciricii	ts for ac	stall3)											
(Required)				PLEASE SUBMIT THE FOLLOWING WITH THE TRF:										
If date of collection is not provided, three calendar days before specimen receipt will be used (for specimens stored longer than 30											n Documents			
days, the day of archive retrieval will be 2. PATIENT INFORMAT		s the date	e of service)			1.	Cillic Notes	2. Pedigree	٥.	insurance	Caru a	na Autho	nizatio	on Documents
Legal Name (Last, First, MI)	ION							Date of Birth (MM)	(DD/YY)	Sex Assign	ed Ge	ender (optio	onal)	
Legal Name (Last, First, Wil)								at Birth		at Birth		☐ Man ☐ Woman ☐ Nonbinary ☐ Self-described		Nonbinary
Genetic Ancestry: ☐ Ashkena: ☐ Middle Eastern ☐ Native A				•					о ПМ	editerranean		MRN		
Address				City					State	ate Zip				
Mobile #				Email					Preferred Billing ☐ Insurance ☐ Self-pay ☐ Institutional					
3. ORDERING PROVIDE	R INF	ORMA	ATION											
Organization Name, Number				Address	Address				City, State			Zip		
Ordering Provider Name (Last, First), Ambry Number , NPI														
Genetic Counselor/Other Healthcare Professional Name (Last, F				ast, First), Am										
4. PERSONAL AND FAM	AILY F	IISTO	RY OF CAN	ICER Attac	h clinic r	notes and/	or pedigree							
Personal History of Cancer: 🗆 `	Yes □ N	No Ag	ge of Dx:			Metastati	ic: 🗌 Yes 🗎 No	Tumor is ☐ MSI-	High or	·□IHC-Abn	ormal	ICD-10	Code(5)
Testing could aid in systemic th	nerapy a	nd/or s	surgical decision	on-making for	my affe	cted patier	nt 🗌 Yes 🗌 No	Abnormal IHC Re	esult:					
Patient Cancer Type Details:														□TNBC
Family History of Cancer: Ye	s 🗆 No		Known Fami	ial Variant: 🗌 Family 🗎 Self Gene: Variant (c. and/or p.): Ambry ID:										
☐ My patient is the most infor	mative	family r	member availa	able for testing	g. The aff	ected rela	tive and all interv	ening relatives are	either o	deceased or i	unwilling,	/unavailable	e for test	ting.
Relationship to Patient	Mat	Pat	Age at Dx	Family Test	ing and (Cancer Ty _l	pe Details				Reas	on relative	has not	been tested
											□De	eceased 🗆	Decline	s 🗌 No Contact
												□ Deceased □ Declines □ No C		
										□De	☐ Deceased ☐ Declines ☐ No Contact			
									ПДе	□ Deceased □ Declines □ No Contact				
										□ Deceased □ Declines □ No Contact				
5. TEST ORDERS												Jeedased	, 2 000	S Elite contact
REQUIRED: Select a Primary Test Order					Select an Optional Supplemental Test (Per payer policy, all tests in this section will be processed and billed separately; tests may be performed as a reflex.)									
For Patients Meeting BRCA1/2 Testing Criteria				☐ CancerNext® (8824) ☐ CancerNex				t-Expanded® (8875)						
□ BRCA1/2 test				- · ·					nited Evidence Pancreatitis					
For Patients Meeting Colorectal Cancer Syndrome Testing Criteria (Lynch)						☐ BRCANext® (8857) ☐ CustomNext-Cance			t-Cancer®	(9511)				
Lynch Syndrome test: ☐ MLH1, MSH2, MSH6, PMS2, EPCAM						Add on: ☐ Limited Evidence Notes: ☐ Specific Site Analysis (5555): Proband rep				port is required.				
For Patients Meeting Colorectal Cancer Syndrome Testing Criteria (polyposis)									Variant (c./p.):					
Polyposis test: ☐ APC/MUTYH					Other:									
Other:					Other Supplemental Test Options (Select if applicable)									
□ None of the above (patient does not meet any genetic testing criteria) Collection Assistance: □ Phlebotomy draw □ Send saliva kit to patient □ Send buccal sw.					☐+RNAinsight® (Not available with BRCAplus or STAT orders; PAXgene® tube required for RNA)									
STAT TEST: Date results ne				•			· · · · · · · · · · · · · · · · · · ·	□Voc □Nic □I	Inkna	ın Data C	onotic C	uncolina	ac Davf-	rmod:
JIMI IEJI. 🔲 Date results ne	euea (I	i Kilowr	i)	V\	vas gene	uc counse	ing completed?	☐ Yes ☐ No ☐ l	TIKLION	ni Date G	eneuc Co	ounseling w	as rerio	iiiieu.



Patient Name:	DOB:

TERMS AND CONDITIONS

Patient Acknowledgement: I acknowledge that the information provided by me is true and correct. For direct insurance billing: I authorize my insurance benefits to be paid directly to Ambry Genetics Corporation (Ambry), authorize Ambry to release medical information concerning my testing to my insurer, to be my designated representative for purposes of appealing any denial of benefits as needed and to request additional medical records for this purpose. I understand that I am financially responsible for any amounts not covered by my insurer and responsible for sending Ambry money received from my health insurance company.

□ I agree to be contacted regarding future research studies for which I may be a candidate. Any future research projects will be subject to a separate informed consent process and participation is voluntary. Learn more about Ambry's privacy practices at https://www.ambrygen.com/legal/notice-of-privacy-practices.

For patient payment by credit card: I hereby, authorize Ambry Genetics Corporation to bill my credit card as indicated above. In order to expedite consideration for eligibility for Ambry's Patient Assistance Program, please provide the total annual gross household income: \$\frac{1}{2}\$ and the number of family members in the household supported by the listed income: \$\frac{1}{2}\$ I authorize Ambry Genetics Corporation to verify the above information for the sole purpose of assessing financial need, including the right to seek supporting documentation.

For NY Residents: I understand that New York State law requires Ambry Genetics to destroy my sample at the end of the testing process or not more than sixty days after the sample was taken. By checking this box, I agree that Ambry Genetics will instead retain my sample for at least 6 months after the testing above has been completed, and may (a) retain and use samples and health information for an indefinite period of time in accordance with applicable law; and (b) de-identify such samples and information and use and share the resulting de-identified samples and information in accordance with applicable law.

Medical Professional: Confirmation of Informed Consent, Pre-test Genetic Counseling, and Medical Necessity for Genetic Testing

I confirm that the genetic test ordered is medically appropriate. All information on this TRF is true to the best of my knowledge. I also confirm that the patient has consented to proceed with genetic testing, including the transfer and processing of their sample and personal/sensitive information in the United States. I agree to allow Ambry Genetics to facilitate the provision of pre-test genetic counseling services by a third-party service, as required by the patient's insurance provider.

Supplemental Information

Hereditary Cancer Multi-Gene Tests

TEST NAME	TEST CODE	GENES	
Pan-cancer		·	
CancerNext® (40 genes)	8824	APC, ATM, AXIN2, BAP1, BARD1, BMPR1A, BRCA1, BRCA2, BRIP1, CDH1, CDKN2A, CHEK2, EPCAM, FH, FLCN, GREM1, HOXB13, MBD4, MET, MLH1, MSH2, MSH3, MSH6, MUTYH, NF1, NTHL1, PALB2, PMS2, POLD1, POLE, PTEN, RAD51C, RAD51D, RPS20, SMAD4, STK11, TP53, TSC1, TSC2, VHL	
CancerNext- <i>Expanded</i> ® (77 genes or up to 90 genes w/ add-ons)	8875	AIP, ALK, APC, ATM, AXIN2, BAP1, BARD1, BMPR1A, BRCA1, BRCA2, BRIP1, CDC73, CDH1, CDK4, CDKN1B, CDKN2A, CEBPA, CHEK2, CTNNA1, DDX41, DICER1, EGFR, EPCAM, ETV6, FH, FLCN, GATA2, GREM1, HOXB13, KIT, LZTR1, MAX, MBD4, MEN1, MET, MITF, MLH1, MSH2, MSH3, MSH6, MUTYH, NF1, NF2, NTHL1, PALB2, PDGFRA, PHOX2B, PMS2, POLD1, POLE, POT1, PRKAR1A, PTCH1, PTEN, RAD51C, RAD51D, RB1, RET, RPS20, RUNX1, SDHA, SDHAF2, SDHB, SDHC, SDHD, SMAD4, SMARCA4, SMARCB1, SMARCE1, STK11, SUFU, TMEM127, TP53, TSC1, TSC2, VHL, WT1	
		Optional Add-on 1 - Limited Evidence Genes (8 genes): ATRIP, EGLN1, KIF1B, MLH3, PALLD, RAD51B, RNF43, TERT	
		Optional Add-on 2 - Pancreatitis Genes (5 genes): CFTR, CPA1, CTRC, PRSS1, SPINK1	
STAT Breast Management	T		
BRCAPlus® (13 genes)	8836	ATM, BARD1, BRCA1, BRCA2, CDH1, CHEK2, NF1, PALB2, PTEN, RAD51C, RAD51D, STK11, TP53	
Breast & gynecologic			
BRCANext® (19 genes or up to 26	8857	ATM, BARD1, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, EPCAM, MLH1, MSH2, MSH6, NF1, PALB2, PMS2, PTEN, RAD51C, RAD51D, STK11, TP53	
genes w/ add-on)		Optional Add-on - Limited Evidence Genes (7 genes): ATRIP, CDC73, FH, NTHL1, POLD1, POLE, RAD51B	
Colorectal & polyposis			
ColoNext® (21 genes or up to 26 genes w/ add-on)	8821	APC, AXIN2, BMPR1A, CDH1, EPCAM, GREM1, MBD4, MLH1, MSH2, MSH3, MSH6, MUTYH, NTHL1, PMS2, POLD1, POLE, PTEN, RPS20, SMAD4, STK11, TP53	
		Optional Add-on - Limited Evidence Genes (5 genes): ATM, CHEK2, CTNNA1, MLH3, RNF43	
Customizable			
CustomNext-Cancer® (up to 90 genes) Required: complete CustomNext-Cancer supplemental form. ambrygen.com/forms		To order all genes on Ambry's oncology menu, please order CancerNext-Expanded.	
	9511	AIP, ALK, APC, ATM, ATRIP, AXIN2, BAP1, BARD1, BMPR1A, BRCA1, BRCA2, BRIP1, CDC73, CDH1, CDK4, CDKN1B, CDKN2A, CEBPA, CFTR, CHEK2, CPA1, CTNNA1, CTRC, DICER1, DDX41, EGFR, ELGN1, EPCAM, ETV6, FH, FLCN, GA GREM1, HOXB13, KIF1B, KIT, LZTR1, MAX, MBD4, MEN1, MET, MITF, MLH1, MLH3, MSH2, MSH3, MSH6, MUTYH, NF2, NTHL1, PALB2, PALLD, PDGFRA, PHOX2B, PMS2, POLD1, POLE, POT1, PRKAR1A, PRSS1, PTCH1, PTEN, RAD51 RAD51C, RAD51D, RB1, RET, RNF43, RPS20, RUNX1, SDHA, SDHAF2, SDHB, SDHC, SDHD, SMAD4, SMARCA4, SMARCB1, SMARCE1, SPINK1, STK11, SUFU, TERT, TMEM127, TP53, TSC1, TSC2, VHL, WT1	
		For Medicare Patients: At a minimum, the following core genes must be included in the panel to ensure Medicare coverage: APC, ATM, BRCA1, BRCA2, CHEK2, EPCAM, MLH1, MSH2, MSH6, PALB2, PMS2, PTEN, TP53.	
Syndrome specific			
Adenomatous polyposis	8726	APC, MUTYH	
BRCA1/2-associated hereditary breast and ovarian cancer (HBOC)	8838	BRCA1, BRCA2	
Lynch syndrome	8517	MLH1, MSH2, MSH6, PMS2 + EPCAM del/dup	



Patient Name:	DOB:	_
---------------	------	---

Supplemental Information

Specimen Requirements

Blood/saliva from patients with a history of allogenic bone marrow or stem cell transplant cannot be used for genetic testing. Blood/saliva from patients with active hematological disease is not recommended. An alternative specimen may be needed. Please see ambrygen.com/specimen-requirements for details.

Buccal swab samples from patients with a history of allogenic bone marrow or stem cell transplant should not be used for genetic testing. For these patients, an alternative specimen (e.g. cultured fibroblasts) is required. Testing on buccal swab samples from patients with active hematological disease is not recommended. An alternative specimen (e.g. cultured fibroblasts) is recommended. Please see ambrygen.com/specimen-requirements for details.

Specific site analysis for variants identified at an external laboratory must be accompanied by a copy of the original testing report. A positive control from a known positive family member is recommended (required for prenatal testing).

Reflex or Concurrent Testing

Concurrent testing is when multiple tests are initiated at the same time. When multiple tests are ordered on the same test requisition form, testing will be run concurrently unless otherwise specified.

Reflex testing is when a subsequent test is initiated pending the outcome of the initial test. Reflex testing may result in delayed reporting of results.

For reflex test orders:

- Any diagnostic finding at any step will result in cancellation of any subsequent reflex tests.
- Non-diagnostic findings (including VUS or Uncertain results) will automatically reflex to the subsequent test.
- Secondary findings results do not impact whether a subsequent test is initiated or canceled.

When ordering STAT panels (such as BRCAplus*), the results of the STAT panel will be prioritized and reported with a shorter turnaround time, even if the tests were run concurrently.

Known Familial Variants

Variant-specific report comments about the presence or absence of known familial variant(s) require the "Known Familial Variant" section of this form to be completed accurately, including an internal Ambry reference ID and/or a copy of the positive family member's lab report. Acceptable types of Ambry identifiers include:

- Accession number
- Order number
- Name and date of birth

Variant requests without an internal Ambry reference ID or positive family member's lab report will not receive a variant-specific report comment.